Here are the 10-K annual reports from Lunai Bioworks Inc (LNAI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LNAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LNAI filings page.
Lunai Bioworks Inc. (LNAI) reported $51,992 in service revenue for the year ended June 30, 2026, compared with none in 2025, and a net loss of $3,562,479 versus $178,007,489. The 2025 results included $170,419,429 of goodwill impairment. In 2026, the company recorded a $12,019,227 gain on the bankruptcy of a subsidiary and a $7,415,708 loss on extinguishment of debt. Operating activities used $5,288,197 in cash, while financing activities provided $6,391,458; cash and cash equivalents were $1,713,653 at June 30, 2026.
On May 1, 2026, Lunai acquired Neurobridge IP Holdings for Series B Convertible Preferred Stock valued at $1.84 million. Its rights to the N2B platform are limited to biodefense medical countermeasures and Alzheimer’s disease. Lunai reported substantial doubt about its ability to continue as a going concern. As of October 13, 2026, it had less than one month of available cash resources under its current operating plan and said additional financing was needed to fund near-term operations. The company reported a working capital deficit of $16,874,093 at June 30, 2026.